Abstracts tagged "Psoriatic arthritis"

Abstract Number: L01 • 2019 ACR/ARP Annual Meeting
Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Yinzhu Jin ¹, Hemin Lee ¹, Moa Lee ², Joan Landon ³, Joseph Merola ⁴, Rishi Desai ⁵ and Seoyoung C. Kim¹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, ²University of North Carolina Chapel Hill, Chapel Hill, North Carolina, ³Brigham and Women's Hospital, Boston, Massachusetts, ⁴Harvard Medical School, Brigham and Women's Hospital, Boston, ⁵Brigham and Women's hospital, Boston
Background/Purpose: The risk of serious infection when using disease-modifying antirheumatic drugs (DMARDs), including biologic drugs is one of the major concerns for psoriasis/psoriatic arthritis (PsO/PsA)…
Abstract Number: L20 • 2019 ACR/ARP Annual Meeting
A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
Josef Smolen¹, Peter Nash ², Hasan Tahir ³, Hendrik Schulze-Koops ⁴, Lingnan Li ⁵, Maja Hojnik ⁶, Amanda Gellett ⁵, Soyi Liu-Leage ⁷, Sreekumar Pillai ⁷ and Philip J. Mease ⁸, ¹Medical University of Vienna, Vienna, Austria, ²Griffith University, Brisbane, Queensland, Australia, ³Royal Free London NHS Trust, London, United Kingdom, ⁴Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, ⁵Eli Lilly and Company, Indianapolis, Indiana, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Indianapolis, ⁸Swedish Medical Center and University of Washington, Seattle, Washington
Background/Purpose: Multiple biologic DMARDs (bDMARDs) are available for treatment of PsA, but there are few direct comparisons of their efficacy and safety. Furthermore, efficacy of…
Abstract Number: 582 • 2019 ACR/ARP Annual Meeting
Rheumacheck – Spondyloarthritis: Comprehensive Fast-track Diagnosis Program. What Benefits Does It Offer in a Developing Country?
Einer Sanchez Prado¹, Alvaro Ruta ², Jessica Torres Chichande ², Santiago Ruta ³, Sebastian Magri ², Facundo Salvatori ² and Rodrigo Garcia Salinas ², ¹Hospital Italiano de La Plata, La Plata, ²Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, ³Rheumatology Department, Hospital San Martín de La Plata and Rheumatology Unit, Hospital Italiano de La Plata, Argentina., La Plata, Argentina
Background/Purpose: In our region, the lack of knowledge, timely referral and access to laboratory tests and images are the main causes in the diagnostic delay…
Abstract Number: 1087 • 2019 ACR/ARP Annual Meeting
Golimumab Improves Work Productivity and Activity and Quality of Life in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Final Results from a Non-Interventional Study in Germany (GO-ART)
Klaus Krüger¹, Sven Remstedt ², Astrid Thiele ³ and Ines Klaudius ⁴, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheuma Praxis Berlin, Berlin, Germany, ³Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁴MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and tolerability in various randomized clinical trials. Systemic data for GLM regarding health-economic parameters in daily clinical practice…
Abstract Number: 1484 • 2019 ACR/ARP Annual Meeting
The Impact of Time Since First Diagnosis on the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis
Peter Nash¹, Maria Greenwald ², Liang-Hung Lin ³, Wei Yu ⁴, Paul Santos Estrella ⁵, Rajiv Mundayat ⁶, Daniela Graham ⁷ and Douglas Veale ⁸, ¹University of Queensland, Brisbane, Queensland, Australia, ²Desert Medical Advances, Palm Desert, CA, ³AIR, Taichung Tzu Chi Hospital, Taichung City, Taiwan (Republic of China), ⁴Pfizer Inc, Beijing, China (People's Republic), ⁵Pfizer Inc, Makati, Philippines, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland
Background/Purpose: Early identification, diagnosis, and treatment of psoriatic arthritis (PsA) is important in preventing long-term joint damage and disability, and the associated socioeconomic consequences.1 Tofacitinib…
Abstract Number: 1534 • 2019 ACR/ARP Annual Meeting
Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study
Laura Coates¹, Philip Mease ², Dafna Gladman ³, Filip Van den Bosch ⁴, Anna Rychlewska-Hanczewska ⁵, Chantal Tasset ⁶, Luc Meuleners ⁶, Mona Trivedi ⁷, Jingjing Gao ⁷, Robin Besuyen ⁶ and Philip Helliwell ⁸, ¹University of Oxford, Oxford, United Kingdom, ²Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁴Ghent University Hospital, Ghent, Belgium, ⁵5ai centrum medyczne sp. z o.o. sp.k., Poznan, Poland, Poznan, Poland, ⁶Galapagos NV, Mechelen, Belgium, ⁷Gilead Sciences Inc, Foster City, United States of America, Foster City, CA, ⁸University of Leeds, Leeds, United Kingdom
Background/Purpose: Filgotinib (FIL) is an orally administered, selective Janus Kinase 1 (JAK1) inhibitor in development for psoriatic arthritis (PsA). Efficacy and safety of FIL in…
Abstract Number: 2246 • 2019 ACR/ARP Annual Meeting
Symptoms and Impacts in Psoriatic Arthritis: Findings from Qualitative Patient Interviews
Kaleb Michaud ¹, Evo Alemao ², Miroslawa Nowak ³, Rachel Bruce ⁴, Sarah Cantor ⁴, Carlijn Hintzen ⁵, Philip Mease ⁶, Kendra DeBusk² and Alexis Ogdie ⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²Bristol-Myers Squibb, Princeton, ³Bristol-Myers Squibb, Princeton, NJ, ⁴IQVIA, New York, ⁵IQVIA, Amsterdam, Netherlands, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁷University of Pennsylvania, Philadelphia
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease resulting in significant symptom burden.1 Over time and without adequate treatment, PsA can lead to disability…
Abstract Number: 2455 • 2019 ACR/ARP Annual Meeting
Impact of Enthesitis on Patient Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey
Ana-Maria Orbai¹, Birt Julie ², Elizabeth Holdsworth ³, Nicola Booth ⁴, Matthew M. Hufford ², Malatestinic William ², Aubrey Trevelin Sprabery ² and Anthony Reginato ⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Adelphi Real World, Manchester, England, United Kingdom, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Division of Rheumatology, Providence VAMC, Associate Professor in Medicine, The Warren Alpert School of Medicine, Providence
Background/Purpose: Enthesitis, a characteristic clinical feature of psoriatic arthritis (PsA) [1], is a core outcome for PsA clinical trials. While enthesitis is considered important when…
Abstract Number: 2477 • 2019 ACR/ARP Annual Meeting
Burden of Disease at Treatment Initiation Among Biologic-Naïve Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Mei Liu ², Meghan Glynn ³, Kelechi Emeanuru ², Leslie Harrold ⁴, Sven Richter ⁵, Benoit Guerette ⁵ and Philip Mease ⁶, ¹Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Waltham, ⁴Corrona, LLC and University of Massachusetts Medical School, Worcester, MA, ⁵Celgene Corporation, Summit, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Oligoarticular PsA accounts for ≈50% of PsA worldwide, but only a paucity of data describes disease burden among these patients. The Corrona PsA/SpA Registry,…
Abstract Number: 2499 • 2019 ACR/ARP Annual Meeting
Predicting Risk of Developing Psoriatic Arthritis (PsA) in Siblings of Patients with Psoriatic Arthritis
Winifred Badaiki¹, Quan Li ², Tanya Burry ¹, Fiona Landells ¹, Rachel Gehue ¹, Cindy Penney ³, DIanne Codner ¹, Amanda Dohey ¹, Kerri Smith ¹, Fatima Abji ⁴, Dafna Gladman ⁵, Darren O'Rielly ¹, Vinod Chandran ⁶ and Proton Rahman ⁷, ¹Memorial University, St. Johns, Canada, ²Toronto Western Hospital, Toronto, Canada, ³Memorial University, St Johns, Canada, ⁴Memorial University, Toronto, Canada, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶University Health Network, University of Toronto, Toronto, Canada, ⁷Memorial University, St. Johns, NL, Canada
Background/Purpose: Delay in diagnosis of psoriatic arthritis (PsA) has been shown to contribute to poor radiographic and functional outcome and less successful response to treatment…
Abstract Number: 2853 • 2019 ACR/ARP Annual Meeting
The Pattern of Musculoskeletal Complaints in Patients with Suspected Psoriatic Arthritis and Their Correlation with Physical Examination and Ultrasound
Samantha Sarabia ¹, Chandra Farrer ², Jensen Yeung ³, Richard Cook ⁴, Ker-Ai Lee ⁵, Dana Jerome ³ and Lihi Eder⁶, ¹Faculty of Medicine, Queens University, Kingston, Canada, ²University of Toronto, Toronto, Canada, ³University of Toronto, Toronto, ⁴University of Waterloo, Waterloo, Canada, ⁵University of Waterloo, Waterloo, ⁶Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada
Background/Purpose: There is limited information about the constellation of musculoskeletal symptoms experienced by patients with early psoriatic arthritis (PsA). This study aims to describe the…
Abstract Number: 628 • 2019 ACR/ARP Annual Meeting
Pain Perception and Opiate Use Among Patients with Inflammatory Arthritis
Alexis Ogdie¹, Sofia Pedro ² and Kaleb Michaud ³, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Pain is the most common symptom among patients with inflammatory arthritis (IA) and residual pain is common in patients IA despite appropriate treatment. Opiate…
Abstract Number: 1088 • 2019 ACR/ARP Annual Meeting
Does Drug Effectiveness of 2nd and 3rd TNF Inhibitors in Patients with Psoriatic Arthritis Depend on the Reason for Withdrawal from the Previous Treatment? – Results from the EuroSpA Research Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg ¹, Lennart Jacobsson ², Michael J. Nissen ³, Eirik Kristianslund ⁴, Herman Mann ⁵, Maria José Santos ⁶, Manuel Pombo-Suarez ⁷, Dan Nordström ⁸, Ziga Rotar ⁹, Bjorn Gudbjornsson ¹⁰, Fatos Onen ¹¹, Catalin Codreanu ¹², Anne Gitte Loft ¹³, Ulf Lindström ¹⁴, Burkhard Moeller ¹⁵, Joe Sexton ¹⁶, Karel Pavelka ⁵, Anabela Barcelos ¹⁷, Carlos Sánchez-Piedra ¹⁸, Kari K. Eklund ¹⁹, Matija Tomsic ²⁰, Thorvardur J Love ²¹, Gercek Can ²², Ruxandra IONESCU ²³, Marleen van de Sande ²⁴, Irene van der Horst-Bruinsma ²⁵, Gareth Jones ²⁶, Florenzo Iannone ²⁷, Brigitte Michelsen ¹, Lise Hyldstrup ²⁸, Niels Steen Krogh ²⁹, Mikkel Østergaard ³⁰ and Merete Lund Hetland ³¹, ¹EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, ²Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ³University Hospital Geneva, Geneva, Switzerland, ⁴Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁶Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ⁷Rheumatology Unit, Clinical University Hospital of Santiago de Compostela,, Santiago, Spain, ⁸Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ⁹UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹⁰Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹¹Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, ¹²Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ¹⁴University of Gothenburg, Gothenburg, Sweden, ¹⁵University Hospital Bern, Bern, Switzerland, ¹⁶Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ¹⁷Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, ¹⁸Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ¹⁹ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ²⁰Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²¹Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ²²TURKBIO Registry and Division of Rheumatology, School of Medicine Dokuz Eylul University,, Izmir, Turkey, ²³SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁴Amsterdam UMC, Amsterdam, Netherlands, ²⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ²⁶University of Aberdeen, Aberdeen, United Kingdom, ²⁷Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ²⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁹Zitelab / DANBIO, Copenhagen, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ³¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are efficacious in patients with psoriatic arthritis (PsA), but some patients switch to a different TNFi because of adverse…
Abstract Number: 1489 • 2019 ACR/ARP Annual Meeting
Impact of Apremilast on PsA Impact of Disease Core Components in Patients with a Limited Number of Active Joints: Results from a Real-World Study
Tim Jansen¹, Eric-Jan Kroot ², Arie van Vliet ³, Jan Pander ⁴ and Marijn Vis ⁵, ¹Viecuri MC, Venlo, Netherlands, ²Elkerliek, Helmond, Netherlands, ³Celgene, Utretcht, Netherlands, ⁴Celgene, Utrecht, Netherlands, ⁵ErasmusMC, Rotterdam, Netherlands
Background/Purpose: Recent data suggest that patients with moderately active psoriatic arthritis (PsA) and a limited number of active joints have a high likelihood of achieving…
Abstract Number: 1538 • 2019 ACR/ARP Annual Meeting
The Effects of Apremilast Therapy on Deployability in Active Duty U.S. Army Soldiers with Plaque Psoriasis and Psoriatic Arthritis
Andrew Price¹, Vanya Wagler ², Chase Donaldson ¹ and Patrick Mastin ¹, ¹William Beaumont Army Medical Center, El Paso, TX, ²United Regional Physician Group, Wichita Falls, TX
Background/Purpose: Apremilast is a novel oral phosphodiesterase 4 inhibitor that is used for plaque psoriasis (PsO) and psoriatic arthritis (PsA). This medicine is unique in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].